Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This is great, co initiated the halt

<< Previous

Bullboard Posts

Next >>

Comment by Qtrlbderon Feb 17, 2021 7:32pm

152 Views

Post# 32591772

RE:RE:This is great, co initiated the halt

Well well well, all the coach roaches had surface at once. Where were yall today when the sp was trading above 7.00. Now go back to your roach cave and stop spreading fear.

123ABC wrote:
The news is dilution don't see how that's great. Partnership would've been great.

NotBornLastNite wrote:

TSX Symbol: ATE

All Issues: Yes

Reason: Pending News

Halt Time (ET): 4:33 PM